Increased GFAP gene expression is a common feature of CNS injury, resulting in its use as a reporter to investigate mechanisms producing gliosis. AP-1 transcription factors are among those proposed to participate in mediating the reactive response.
| INTRODUC TI ON
Transcription of the GFAP gene is strongly increased by most forms of CNS injury. Identification of the regulatory elements in the GFAP promoter required for this upregulation has been pursued to obtain information about signaling pathways occurring in the injured brain. This study evaluated the participation in the injury response of a consensus binding site for the AP-1 family of transcription factors that is located 1592 bp upstream of the transcription start site of the human GFAP gene. The presence of a similarly located AP-1 binding sequence in the mouse and rat Gfap genes suggests that this site has a regulatory role. The family of AP-1 transcription factors includes c-Jun, JunB, JunD, c-Fos, FosB, Fra-1, and Fra-2 (reviewed in Rylski & Kaczmarek, 2004) . These act as dimers, usually to enhance transcription, but can also serve as inhibitors. To perform this study, we compared the activity of a wild-type GFAP promoter to one in which the AP-1 site was mutated. Transgenic mice were used instead of cultured cells, as we have consistently observed that the activity of the GFAP gene in culture does not accurately report its activity in vivo (de Leeuw et al., 2006; tial for activity of reporter constructs transfected into cultured cells, but to have little to no effect on basal transgene expression in mice. Since cultured astrocytes display some properties of reactive astrocytes, these findings suggested that AP-1 transcription factors are critical for the upregulation of GFAP in injury, but not for its resting level of expression. We have examined this possibility by comparing the injury response in mice of lacZ transgenes driven by human GFAP promoters that contain the wild-type AP-1 binding site to those in which the site is mutated. An intact AP-1 site was found critical for a GFAP promoter response to the three different injury models used: physical trauma produced by cryoinjury, seizures produced by kainic acid, and chronic gliosis produced in an Alexander disease model. An unexpected additional finding was that the responses of the lacZ transgenes driven by the wild-type promoters were substantially less than that of the endogenous mouse GFAP gene. This suggests that the GFAP gene has previously unrecognized injury-responsive elements that reside further upstream of the transcription start site than the 2.2 kb present in the GFAP promoter segments used here.
K E Y W O R D S
aging, Alexander disease, brain injuries, cold injury, female, glial fibrillary acidic protein, gliosis, kainic acid, mice, transgenic, RRID:IMSR_JAX:003487, RRID:IMSR_TAC:fvb, seizures, sex characteristics, STAT3 transcription factor, transcription factor AP-1, transcription, genetic 2006; Yeo, Bandyopadhyay, Messing, & Brenner, 2013) . In particular, such a discrepancy has been observed for the role of the AP-1 site. Previous studies in human glioma cell lines using reporter genes driven by a human GFAP (hGFAP) promoter indicated that the conserved AP-1 binding site is essential for transcription of the gene (Gopalan, Wilczynska, Konik, Bryan, & Kordula, 2006a; Masood, Besnard, Su, & Brenner, 1993) . This was supported by the observation of Gopalan, Wilczynska, Konik, Bryan, and Kordula (2006b) that expression of a dominant negative c-Jun in the U373 glioma cell line abolished endogenous GFAP expression. However, it was subsequently found that mutation of this site in a hGFAP promoter-driven lacZ transgene had little effect on its basal expression in mice (Yeo et al., 2013) . These seemingly disparate findings could be reconciled if the AP-1 site is important for upregulation of the GFAP gene, as occurs in cultured astrocytes, but not for its basal expression in the CNS. To determine if the response of either the wild-type hGFAPlacZ transgene or the AP-1 mutated form depends on the nature of the injury, three different forms of injury were used: excitotoxicity produced by kainic acid (KA)-induced seizures, physical trauma resulting from cryoinjury, and genetic injury involving chronic gliosis produced by transgene-mediated over-expression of human GFAP, which has been used as an Alexander disease (AxD) model (Messing et al., 1998; Messing, Goldman, Johnson, & Brenner, 2001 ; reviewed in Brenner, Goldman, Quinlan, & Messing, 2009 ).
| ME THODS

| Transgenic animals
All experimental protocols were approved by the Institutional Animal Care and Use Committees of the University of Alabama at Birmingham (protocol 07859) and the University of Wisconsin, Madison (protocols G00199, G00321). Mice were maintained in AAALAC approved housing with standard food and water available ad libitum. Previously described lines are the wild-type hGFAPnlacZ lines tg7-2 (Tg(X:GFAP,lacZ)Mes3) (RRID:IMSR_JAX:003487) (Brenner, Kisseberth, Su, Besnard, & Messing, 1994) , gfa2-nlac2 and gfa2-nlac3 (Su et al., 2004) . In this paper, the more descriptive names WT-1, WT-2, and WT-3 will be used for these three lines, respectively. Each of these lines carries the same hGFAP-nlac transgene, which consists of hGFAP bp −2,163 to +47 (RNA start site is +1), with the initiating ATG at +15 mutated to TTG (the gfa2 promoter), placed in front of a nuclear-targeted E. coli lacZ gene, which in turn is followed by a fragment of the mouse protamine-1 gene (mP1). The latter supplies an intron, stabilizing 3′ UTR, and a polyadenylation signal. Also previously described is line 73-7 (TgN(GFAP)Mes10) (Messing et al., 1998) . Newly made lines for this study are WT-4, AP1m-1, AP1m-2, and AP1m-3. Each of these lines carries the same gfa2-nlac transgene just described, except that the promoter starts at -1,757 instead of −2,163. The shorter 5′ extension was used for the mutant transgene because a long polyA stretch immediately upstream of −1,757 compromised accurate amplification when inserting the AP-1 mutation using PCR-based methods. This difference in promoter start point was not expected to have any effect on the promoter injury response based on previous data (Besnard et al., 1991; Lee, Messing, Su, & Brenner, 2008) , and the fact that most of the deleted region, −2,070 to −1,758, is occupied by a primate-specific alu sequence (Roy-Engel et al., 2001 ). As will be noted below, this assumption was verified by the similar expression properties of WT-4 and WT-2. In addition to the shorter 5′ extension, the transgene in the AP1m lines has the consensus AP-1 binding site at −1,592 mutated from TGACTCA to TTCAGAA by transversion of the five internal nucleotides, using methods similar to those described previously (Masood et al., 1993; Yeo et al., 2013) . The presence of the intended mutation was confirmed by DNA sequencing. Diagrams of each of the transgenes are presented in Figure 1 .
The transgenic mice were made at the University of WisconsinMadison in an FVB/N background and then bred to C57BL/6 for at least 10 generations. However, just prior to initiating this study, Bai et al. (2013) reported that hGFAP-driven transgenes lost activity in the C57BL/6 background, but regained activity after 1 to 2 backcrosses to FVB/N. Although it had been our experience that most of our hGFAP-lacZ lines retained activity on C57BL/6, a few had indeed stopped expressing, and had been discontinued.
All mice used in this study were thus backcrossed to FVB/N for at least two generations using breeders obtained from Taconic (RRID:IMSR_TAC:fvb), with the exception of line 73-7, which was continuously maintained on an FVB/N background. Despite the backcrossing to FVB/N, a few mice showed more than a 10-fold reduction in lacZ expression compared to other mice of the same line, prompting exclusion of those samples. This occurred for 1 of 35 WT-2 mice, 6 of 35 WT-3 mice, 1 of 47 WT-4 mice and 4 of 31 AP1m-1 mice, but for none of the 41 WT-1 mice, 32 AP1m-2 mice and 34 AP1m-3 mice used for this study. Ages of mice used were 2.5-9.6 months for the kanic acid (KA) experiments, 2.1-7.4 months for the AxD injury model, and 1.9-12.1 months for the cryoinjury experiments. Mice were assigned to injury or control groups to match as closely as possible the age and sex among the animals available, and had no other distinguishing phenotype. Our
Significance
Astrocytes are abundant cells in the central nervous system (CNS). During CNS injury, astrocytes undergo a response called reactive gliosis, which alters their functions. Some of these changes are beneficial, but others lead to greater injury. Transcription of the GFAP gene increases during reactive gliosis. Understanding the mechanisms responsible for this increase will provide new ideas for how to manage CNS injury. In this study, we show that a DNA binding site for AP-1, a transcription regulatory protein, is required for the injury-induced increase in GFAP. Inhibitors of AP-1 may thus prove useful for managing CNS injury. intention was to use mice without regard to their sex. However, following discovery of the female-predominant seizure syndrome described below, we preferentially used male mice for the remaining experiments (primarily cryoinjury) in order to minimize the frequency with which such seizures would artifactually elevate GFAP promoter activity. The numbers of male (M) and female (F) mice used were as follows (see Tables S1 and S2 After most of the mice needed for this project had been born, a marked increase in mortality was noted among both wild-type and transgenic female mice that had been back-crossed to FVB/N and were four months of age or older. The female death rate increased over five-fold, from about 0.4% per month to about 2.2%, whereas the average male death rate increased only about 1.5-fold, to about 0.6%. In addition, some female mice were observed to be highly aggressive and hyperactive, to adduct rather than extend laterally all four limbs when picked up by the tail, to have seizures and to stare straight ahead. From these observations and results of an autopsy of a female mouse that had seizures, the UAB veterinary staff diagnosed a sudden death and seizure syndrome previously reported for FVB/N mice (Donnelly, 2007; Goelz et al., 1998; Rosenbaum, VandeWoude, & Bielefeldt-Ohmann, 2007) . That this syndrome exits in some FVB/N colonies does not appear to be widely appreciated; since its original description, only a few publications have reported either its presence (Silva-Fernandes, Oliveira, Sousa, & Maciel, 2010; Tennant, Stasiewicz, Eastin, Mennear, & Spalding, 2001) or absence (Buckmaster, Abrams, & Wen, 2017) , and it is not mentioned on the website of Taconic, the source of our FVB/N breeders.
| Injury protocols
The excitotoxic injury was produced by IP injection of KA (Tocris Bioscience) dissolved in PBS at 1 mg/ml, and was performed blinded to genotype. A multiple low dose protocol was used since we confirmed the finding of Tse, Puttachary, Beamer, Sills, and Thippeswamy (2014) that this produces more consistent seizures with lower mortality than a single large bolus. The initial dose was 9 mg/kg, followed an hour later (if needed) by 2.25 mg/kg, and after another hour (if needed) by 4.5 mg/kg. These booster injections were given only if a seizure score of 5 on the scale of McLin and Steward (2006) had not been reached. In most instances, this seizure level occurred after the first or second dose. All surviving animals were used for experiments. Nearly all of these reached a seizure score of at least 4, and met the requirement we set for sample inclusion for each of the injury models of at least a 3-fold increase in endogenous Gfap mRNA compared to uninjured controls.
Acute physical trauma was produced by a widely used cryoinjury procedure (e.g., see Oury, Piantadosi, & Crapo, 1993) , and was performed blinded to genotype. The mouse was anesthetized with isoflurane, hair removed from the incision site, the site cleaned three times with betadine and 70% isopropyl alcohol, and a skin incision made over the dorsal midline of the skull. A 3-mm diameter brass rod probe cooled in isobutane in dry ice was placed in contact with the skull over the right cerebral hemisphere centered between bregma and lambda for 3 s. If a transient white spot was not noted upon removal of the probe, another 3 s contact was performed with a backup cooled probe. The skin incision was then closed with two surgical staples, coated with lidocaine 2% and the mouse returned to the animal facility. F I G U R E 1 Transgene diagrams. hGFAP is the human GFAP DNA fragment used to generate the 73-7 line used as the AxD model (Messing et al., 1998) . The WT-1, -2, and -3 transgene is the previously described gfa2-nlac (Brenner et al., 1994) ; its complete sequence is available from AddGene as part of pGfa2-nLac (Plasmid #53126). WT-4 is identical to WT-1, except that the promoter starts at bp -1757 instead of -2163. The AP1m-1, -2 and -3 transgene is identical to WT-4, except that the AP-1 site has been changed from TGACTCA to TTCAGAA. A chronic gliosis model was produced by crossing WT and AP1m transgenic mice with 73-7 transgenic mice. The latter carry a hGFAP transgene that extends from −6,156 to +11,228, and includes all exons and introns (Brenner et al., 1990 , and unpublished results; Figure 1 ). This transgene causes over-expression of hGFAP, resulting in formation of astrocytic protein aggregates and chronic gliosis, and serves as a model for AxD (Messing et al., 1998; Messing et al., 2001;  reviewed in Brenner et al., 2009 ). The 73-7 transgenic mice weigh about 40% less than wild-type mice when young, but only slightly less as adults. About 7% die before 5 weeks of age of unknown cause, but the rest live a normal life span.
| mRNA analysis
For both the KA and cryoinjuries, tissues were harvested two days after the insult, a time when pilot studies found that the levels of both the endogenous Gfap mRNA and reporter lacZ mRNA had reached a peak that then slowly decayed over several days (data not shown). In the AxD model mice, the elevation of endogenous and reporter mRNAs extends throughout adulthood (Messing et al., 1998) .
Mice were anesthetized with CO 2 , decapitated, and whole brains removed. Tissues were either processed immediately to isolate RNA, or stored in RNA Later (Thermo Fisher Scientific) at 4°C for 1 day and then at −20°C until used. Total RNA was isolated using STAT-60 (Tel-Test). RNA was prepared from whole brain for the KA and AxD experiments, but for the cryoinjury it was isolated from a cortical tissue punch centered on the injury site. Two coronal slices were made at bregma and lambda, and a 1.5-mm tissue punch used to obtain cortical tissue from the remaining cryoinjured right hemisphere.
Visualization under a dissecting scope was used to ensure the tissue punch obtained did not contain underlying white matter. A tissue punch from the corresponding position in the contralateral (uninjured) hemisphere served as the control for cryoinjury; controls for the KA and AxD treatments were uninjured mice carrying the same transgene. In initial experiments these controls were littermates, but since it was found that non-littermates did not yield a greater variation in values than littermates, non-littermates were often used as controls in order to greatly reduce the number of mice required and the associated time and expense.
RNA was reversed transcribed using the TaqMan Gold RT-PCR kit with random hexamer primers (Thermo Fisher Scientific), and quantitative real time PCR was performed on a StepOne Real-Time PCR machine (Thermo Fisher Scientific) using Master Mix and probe/ primer sets from Thermo Fisher Scientific. The probe/primer sets were 4352339E for mouse Gapdh, Mm01253033_m1 for mouse Gfap and Hs00909238_g1 for human GFAP. A custom set was used for lacZ, consisting of forward primer AAGATGTCGCAGACGGAGGA, reverse primer GACTTGCTATTCTGTGCATC, and 6FAM labeled probe GCCGCTCATACACCATAA. These primers amplify an mP1 sequence at the 3' end of the lacZ transgene, and flank the mP1 intron (see Figure 1 ). Gapdh and Gfap mRNA assays were multiplexed, whereas lacZ mRNA was assayed singly (trial experiments showed that Gapdh amplification interfered with that of lacZ, perhaps due to the relatively low level of lacZ mRNA). mRNA levels are expressed in arbitrary units normalized to Gapdh obtained by subtracting the Gapdh mRNA CT value for a sample from the CT value for the given target, using the difference as the negative exponent of 2, and multiplying by 1,000. Responses of mGfap and the lacZ transgene to injury were assessed by comparison to controls run on the same plate.
| Sample exclusion criteria
Samples were excluded if injury did not produce at least a 3-fold increase in endogenous mGfap mRNA. They were also excluded if the Gapdh CT value was more than 2 units higher than the median for a given assay set, thereby indicating a poor RNA preparation (15 of 551 samples were excluded by this criterion); or if the lacZ mRNA level was less than 1/10th the median for that line, indicating a partial shutoff of transgene expression (12 samples excluded). As noted above, the seizure syndrome was presumably responsible for some of the uninjured control mice having highly elevated mGfap transcript levels (Table S1 ). However, such samples could not be identified for exclusion because of a continuum of high to low values (Table S1 ), probably due to the seizures having occurred at different times prior to sacrifice, and the elevated levels of Gfap mRNA having decayed for variable times. Thus, samples were excluded solely on the basis of being statistical outliers, resulting in removal of just 7 of the 124 controls. As a result, some of the included KA and AxD controls almost certainly had elevated mGfap mRNA levels due to the seizure syndrome. The effect of these elevated control values on interpretation of the results is described in the Discussion. In contrast to mGfap, no significant seizure syndrome effect was observed for the lacZ mRNA values for the controls (Table S1 ), This is likely due to the lacZ mRNA half-life being just a minute or two (Pedersen et al., 2011) , whereas that for Gfap mRNA is 10-20 hr (Neary, Whittemore, Zhu, & Norenberg, 1994; Pedersen et al., 2011) .
| Statistical analysis
After all data were accumulated, a modest increase in controls of mGfap RNA level with mouse age was noted of about 7% per month (Table S1 ). Accordingly, when comparing the mGfap mRNA level of an experimental mouse to that of the controls for the KA and AxD analyses, each control mGfap value was adjusted for any age difference between it and the injured mouse sample before determining the mGfap injury response for that sample. Since the ages of the control and injury mice were generally closely matched for each experiment, most corrections were quite small compared to the mouse-to-mouse variation in injury response; the median adjustment was 6%, only 9 of 111 samples had a correction >20%, and the maximum correction was 40%. No correlations were observed among the controls between age and lacZ mRNA level, or between mGfap level and backcross number, sex or lacZ level. 
Two-tailed t-tests
| RE SULTS
| Response of wild-type hGFAP promoter to injury
To determine the contribution of the GFAP consensus AP-1 binding site to its response to injury, we compared the fold increase in expression of a transgene carrying a wild-type hGFAP-lacZ reporter to that of one with a mutated AP-1 site. In order to determine the success of the injury protocols, the fold increase in expression of the endogenous mGfap gene was also measured. Unexpectedly, the wildtype hGFAP-lacZ transgenes were found to respond much less to injury than the endogenous mGfap gene. The injury-induced increase in lacZ mRNA as a percentage of that for the endogenous mGfap mRNA ranged from a statistically insignificant 0.1% (cryoinjury of line WT-3) to a maximum of 43.2% (AxD model of line WT-2) ( Table 1 ).
The data in Table 1 suggest that the response of the hGFAP-lacZ transgenes to injury is line-dependent, and this was confirmed by statistical analysis. When the lacZ response data for the three injury models were combined, no statistical difference was found between the responses of lines WT-1 and WT-3 or between lines WT-2 and WT-4 (Dunn's post hoc comparison, p > 0.999); but there was a significant difference between the responses of both WT-1 and WT-3 compared to that of both WT-2 and WT-4 (p < 0.0001).
The data in Statistical analysis comparing the injury responses for a given wildtype line found significant differences in the responses to different injuries for some comparisons, but not for others. For example, post hoc comparisons using the Tukey HSD test indicated that the response of WT-1 to AxD was significantly different from that to KA (p = 0.034) or cryoinjury (p = 0.002), but the difference between the responses to KA and cryoinjury were not significant (p = 0.349). When the data were pooled by injury for all four WT lines, no significant difference was found between the responses to KA and AxD (p = 0.338), but the responses to both of these injury models was significantly greater than that to cryoinjury (p = 0.002 and p < 0.0001, respectively).
| Basal activity of the AP-1 mutated hGFAP promoter
It was previously reported that mutation of the AP-1 site had no effect on the basal activity of a derivative of the hGFAP promoter shorter than that used here (Yeo et al., 2013) . That promoter, denoted ABC1D (Lee et al., 2008) , contains bp -1,757 to −1,256 linked to bp −132 to +47. A similar lack of effect of the AP-1 mutation was observed in this study for the longer hGFAP promoters used: lines WT-1 to WT-4 had median lacZ mRNA levels of 1.35, 0.66, 1.15, and 2.02, respectively (average = 1.29); whereas lines AP1m-1, AP1m-2, and AP1m-3 had median values of 1.06, 3.37, and 0.26 (average = 1.56) (Table S1 ). Statistical analysis found no significant difference between the wild-type and AP-1 mutant lines for basal lacZ expression (t 5 = 0.3163, p = 0.765, n = 4,3).
| Injury response of the AP-1 mutated hGFAP promoter
Despite the relatively low injury response of the four WT hGFAP-lacZ transgenes compared to mGfap, each displayed a statistically significant (p < 0.05) increase in lacZ mRNA for each of the three injury models, except for the response of line WT-3 to AxD and cryoinjury (Table 1 ). In contrast, among the three AP-1 mutant lines, the only statistically significant responses were that of AP1m-2 to KA and AxD. Combining the data for the three injury models for each of the four WT lines showed that their aggregate response was significant (Welch t 11 = 4.8, p = 0.001, n = 9,12), whereas the combined results for the AP-1 mutant lines was not (Welch t 8 = 0.74, p = 0.479, n = 7,9).
In addition, the response of the WT lines significantly differed from that of the AP-1 mutant lines (U = 6.0, p = 0.0002, n = 12,9). Thus, presence of the AP-1 site contributes to the injury response of the hGFAP promoter.
| Injury response of an extended hGFAP promoter
The weaker response to injury of the wild-type hGFAP transgenes compared to the endogenous mGfap gene raises the possibility that the hGFAP promoter used lacks some injury-responsive elements.
The hGFAP 73-7 transgene present in the AxD model mice includes considerably more hGFAP sequence than the promoters used here for lacZ expression (Figure 1) , and thus might contain additional injury response elements within its expanse. Whereas the hGFAP sequence used in WT-1, WT-2, and WT-3 promoters extends from nucleotide −2,173 to +47, that in the 73-7 transgene extends from −6,156 to +11,228. This sequence includes all exons and introns (Brenner et al., 1990, and unpublished results) , allowing the hGFAP transcript to be used as the transgene reporter. To determine its injury response, hGFAP mRNA expression in young pups, for which gliosis is not yet significant, was compared to that in adults. The data, presented in Figure 2 , show a high signal-to-noise ratio for detection of the hGFAP mRNA in the AxD mice (compare the hGFAP values for the negative control pups to those for the 73-7 pups). The data also show only a slightly higher level of mGfap mRNA in the eight-day old pups with the 73-7 transgene compared to those without the transgene (1.14-fold increase), confirming little if any gliosis at this age. Comparison of expression levels in the adult 73-7 mice and pups yielded a 4.7-fold increase in mGfap mRNA and a 2.8-fold increase in hGFAP mRNA, corresponding to a transgene response that is 49% that of the endogenous mGfap gene.
| Effect of age on the injury response
The broad age range for the mice used in these experiments provided both an opportunity to determine if the responses of the endogenous mGfap gene and the lacZ transgenes changed with age, and a possible confound if a large age effect were present. As shown in Figure 3a , there is indeed a significant age dependence of the endogenous mGfap response to the AxD injury (p = 0.0002), with the injury-induced increase falling from about 9-fold at 2 months to about 6-fold at 7 months. There was also a trend toward a decrease in the mGfap KA response with age (p = 0.062), but no effect of age for the cryoinjury response (p = 0.123). However, the parameter of interest for this study, the lacZ transgene response compared to that for the endogenous Notes. n is number of control samples, number of injury samples. For cryoinjury, two kinds of controls were used: the levels of mGfap and lacZ mRNAs present in the injured area were compared to the levels in the corresponding region of the uninjured area (same n for injured and this control), and the fold differences obtained then compared to the fold differences between similar hemispheric regions in 11 uninjured mice (this in the n listed in the table). mGfap fold change is the median value for the fold change in mGfap mRNA. LacZ as % mGfap is the injury-induced change in lacZ mRNA as a % of that for mGfap. This was calculated separately for each sample as 100(lacZ fold change -1)/(mGfap fold change -1) and the median value reported. p-value is for the significance of the change in lacZ mRNA following injury; p-values > 0.05 are in gray fill, and those marked with an ( † ) are for the significance of the observed decrease in lacZ mRNA following injury. Details for statistics are as follows (line/injury): WT-1/KA: U = 21, n = 10,11; WT-2/KA: WelchT 5 = 2.660, n = 5,6; WT-3/KA: T 4 = 3.247, n = 3,3; WT-4/KA: T 11 = 5.940, n = 7,12; AP1m-1/KA: U = 6.0, n = 3,7; AP1m-2/KA: WelchT 9 = 2.585, n = 6,8; AP1m-3/KA: U = 4.5, n = 5,5; WT-1/AxD: U = 7.0, n = 9.7; WT-2/AxD: U = 0.00, n = 7,7; WT-3/AxD: U = 0.00, n = 3,4; WT-4/AxD: U = 0.00, n = 6,5; AP1m-1/AxD: U = 4.0, n = 4,4; AP1m-2/AxD: U = 3.5, n = 5,6; AP1m-3/AxD: U = 9.0, n = 5,6; WT-1/cryo: U = 28.00, n = 11,11; WT-2/cryo: U = 0.00, n = 11,5; WT-3/cryo: U = 56.5, n = 11,15; WT-4/cryo: U = 0.00, n = 11,6; APm-1/cryo: U = 27.5, n = 11,6; APm-2/cryo: U = 11.0, n = 11,6; APm-3/cryo: U = 21, n = 11,7. The underlying data for this table are presented in Table S2 .
TA B L E 1 Responses of hGFAP-lacZ transgenes to injuries mGfap gene, showed no apparent effect of age for the injury responses of either the WT or AP1m mice (Figure 3b & c) . Thus no corrections of the injury responses were required for the age differences among the animals.
| Effect of sex on the injury response
There was no difference between male and female mice in their mGfap response to either the AxD model (U = 181, p = 0.833, n = 21,18) or to cryoinjury (U = 262.50, p = 0.643, n = 41,14).
However, female mice responded significantly less strongly to KA than male mice, the median fold-increases in mGfap being 9.5 and 14.9, respectively (U = 194.50, p = 0.012, n = 22,30). Similar to the effect of age, the critical parameter of the KA-induced increase in lacZ mRNA as a percent of that for the endogenous mGfap gene showed no apparent effect of sex (WelchT 29 = 1.757, p = 0.090, n = 12,20); indicating that sex similarly affected the responses of both mGfap and the transgenes (data for these statistics are in Table   S2 ). Thus no corrections were needed for differing numbers of male and female mice in the experimental groups.
Female mice were previously suggested by Twele, Tollner, Brandt, and Loscher (2016) to be less sensitive to KA in certain conditions than male mice. They observed that following intrahippocampal KA injection under choral hydrate anesthesia, female mice did not display the generalized convulsions during status epilepticus observed for male mice. This difference was not present when isoflurane was the anesthesia. Our mice received KA systemically by IP, in the absence of anesthesia.
| D ISCUSS I ON
The reactive response of astrocytes is complex, including both changes that limit damage and contribute to recovery and others that exacerbate injury (reviewed in Sofroniew, 2009 ). The ability to understand and control gliosis is thus of considerable clinical interest. Due to its almost universal upregulation in response to CNS injury, transcription of the GFAP gene has been a common subject of these investigations. In this study, we investigated the role of AP-1 transcription factors in the injury-induced increase in GFAP gene activity by determining the effect of mutation of the consensus AP-1 site in the GFAP promoter. This work was prompted by the seemingly contradictory results that the AP-1 site was required for GFAP promoter activity in transfected glioma cells, but not in mice (Yeo et al., 2013) . Since cultured glioma cells share properties with reactive astrocytes (Cahoy et al., 2008; Nakagawa & Schwartz, 2004 ), but basal promoter activity was measured in the mice, this discrepancy could be explained if AP-1 transcription factors were critical for GFAP upregulation in the reactive response but unimportant for its basal expression. Our observations support this conclusion.
The average basal (uninjured) level of lacZ mRNA expression of the three AP1m transgenic lines did not differ significantly from that of the four WT lines (1.42 vs. 1.31, respectively). In contrast, whereas the group response of the WT lines to the three injuries was significant (p = 0.001), the group response of the AP1m lines was not (p = 0.479). These data thus strongly suggest that the AP-1 binding site in the GFAP promoter is critical for the increased transcription of the gene that occurs in response to several different CNS injuries, but is not involved in its basal level of expression. A caveat is that since entire brain hemispheres were used for these measurements, it is possible that basal expression could be affected in a subpopulation of brain astrocytes or in the spinal cord.
Several previous reports have suggested that AP-1 transcription factors contribute to the increased GFAP mRNA and protein levels in reactive astrocytes, but did not distinguish between direct and indirect effects. For example, correlations between activation of AP-1 proteins and GFAP transcription were observed by Pennypacker, Thai, Hong, and McMillian (1994) , Pozas, Aguado, and Ferrer (1999) , Hashimoto et al. (2005) , Cole-Edwards, Musto, and Bazan (2006), Tang, Xu, and Goldman (2006) and Zeng et al. (2011) . Consistent with the results reported here, Raivich et al. (2004) found that knockout of c-jun in the mouse had no effect on basal expression of Gfap, but attenuated its increase in response to facial nerve axotomy.
Other investigations have suggested a link between AP-1 activity and GFAP expression by interfering with signaling. Using cultured rat astrocytes, Gadea, Schinelli, and Gallo (2008) observed that treatment with endothelin led to an increase in GFAP protein that was accompanied by increased c-jun mRNA and protein, as well as F I G U R E 2 Injury response of the 73-7 transgene. The four transgene negative (control) and four 73-7 positive pups were all eight-day-old littermates. The adults (age in months) were each from a separate litter. The mRNA levels for mGfap and hGFAP were measured as described in Methods. The bar graph presents the average mRNA levels relative to the average for the 73-7 eightday-old pups, with each individual value represented by a small circle. Vertical lines at the top of each bar represent the standard deviation. Within each mRNA type, the statistical differences between either the control or the adult group and the 73-7 eightday-old pups was p < 0.0001 (Tukey post hoc), indicated by *** above the bar value, except that the difference for mGfap between the eight-day control and 73-7 pups was not significant (p = 0.402). Note that the hGFAP mRNA levels for the controls were too low to be visualized. Actual numerical values are presented in the inserted table.
phosphorylation of JNK and c-Jun. Treatment of the cells with either a MEK inhibitor or JNK kinase inhibitor had no effect on the GFAP increase, but when added together the increase was completely blocked. Since the MEK pathway leads to phosphorylation of c-Fos and the JNK pathway to phosphorylation of c-Jun, this finding suggested that AP-1 is required for the upregulation of the Gfap gene in response to endothelin. Using a cell culture scratch model for astrogliosis, Gao et al. (2013) found the increase in Gfap mRNA and protein dependent on an influx of calcium, which increased phosphorylation of JNK and c-Jun. Inhibition of JNK activity prevented both c-Jun phosphorylation and the GFAP increase. Inhibitors of other mitogen activated protein kinases or JAK-STAT were without effect, indicating primacy of AP-1 in this injury model.
Our experimental manipulation was limited to mutation of the consensus AP-1 site in the GFAP promoter, thereby providing the first evidence for AP-1 transcription factors acting directly on the GFAP gene to increase its activity in response to injury. Our findings also confirm and extend a prior observation that mutation of the AP-1 binding site in a truncated hGFAP promoter had no significant effect on basal expression (Yeo et al., 2013) , despite such mutations blocking AP-1 binding (Masood et al., 1993) and strongly inhibiting activity in transfected cells (Gopalan et al., 2006a (Gopalan et al., , 2006b Masood et al., 1993) . This is consistent with suggestions that cultured astrocytes better model reactive astrocytes than resting astrocytes (Cahoy et al., 2008; Nakagawa & Schwartz, 2004) .
The injury response of the four WT hGFAP-lacZ lines was consistently less than that of the endogenous mGfap gene, ranging from an insignificant 0.1% of that of mGfap for cryoinjury of line WT-3, to a high of 43% for the AxD injury model of line WT-2. The median response of the transgenes for all four lines for the three injury models was 14.8% that of the endogenous mGfap gene. This value might even be an overestimate of the relative response of the transgenes, due to the presence of the seizure syndrome in our colony described in Methods. The presence of this syndrome almost certainly resulted in some of the KA and AxD controls having elevated mGfap mRNA levels. This would result in the calculated mGfap mRNA fold F I G U R E 3 Effect of age on the injury responses of mGfap and lacZ. a. Responses of the endogenous mGfap gene. Data are pooled for all lines. The Y-axis is the fold increase of mGfap mRNA compared to controls. b. Responses of the lacZ transgene of the WT-1, WT-2, WT-3, and WT-4 lines. The Y-axis is the increase in lacZ mRNA as a percent of the increase in mGfap mRNA for the same animal. Since different lines respond to different extents, the responses for each line were divided by the average response for that line so the data could be pooled to achieve a higher n value. Thus the lacZ responses have an overall average of 1.0. c. Responses of the lacZ transgene of the AP1m-1, AP1m-2, and AP1m-3 lines. Data were normalized as described for panel B. Linear regression was performed using GraphPad Prism version 7.02 increases in those injury models being lower than their true value.
Since the transgene responses are compared to that of the endogenous mGfap gene, these lower values for the mGfap response would cause the relative injury response of the transgenes to KA and AxD to be overestimated. The seizure syndrome is not an issue for the cryoinjury data, since the uninjured hemisphere of the same animal was used as the control.
The blunted upregulation of lacZ compared to the endogenous mGfap could be due to several factors, including a human/mouse species difference, cryptic negative elements in the lacZ reporter, or response elements residing outside of the hGFAP promoter used. A species difference appears unlikely from results of Mucke, Oldstone, Morris, and Nerenberg (1991) using a transgene in which a lacZ reporter was embedded in the first exon of a mouse Gfap genomic clone. This mouse clone started at -1,980 (Johnson et al., 1995) , which is similar to ours (-2,163), and extended downstream to about +11,000, which is similar to the termination site of our 73-7 transgene (+11,228). In response to a needle stab wound, lacZ mRNA encoded by this transgene reached a peak 3.4-fold higher than its basal level, whereas that for mGfap increased 9.8-fold (data obtained from Figure 4 of Mucke et al., 1991) . Thus the response driven by this mouse Gfap promoter was about 35% that of the endogenous Gfap gene.
The possibility of negative elements in the lacZ reporter or the presence of injury-responsive elements lying further upstream of -2,163 is suggested by findings of Zhu et al. (2004) 
using a mouse
Gfap promoter that begins at about -12,000 and drives a luciferase reporter (the 3′ end of the promoter was not specified, but presumably is near the RNA start site). They observed that KA intoxication yielded a 10.7-fold increase in luciferase mRNA compared to a 7.4-fold increase in mGfap mRNA (data obtained from Figure 2b ).
However, more equivocal results were obtained by Jany, Hagemann, and Messing (2013) using the same mGfap-luc transgenic line when examining the response in an AxD mouse model. This mouse model has phenotypic similarities to the 73-7 line used in our present study, but was made by inserting a human AxD-causing missense mutation into the mouse Gfap gene (Hagemann, Connor, & Messing, 2006) . Surprisingly, they found that the injury response of the reporter mRNA relative to mGfap mRNA was highly dependent on the brain region examined. For example, the reporter increased only about 56% as much as the endogenous mGfap mRNA in the olfactory bulb and hippocampus, but about 500% more than endogenous Gfap mRNA in the brain stem and spinal cord (data obtained from their Figure 2 ). Since only a single reporter line was examined (as was also the case for the Mucke et al. (1991) and Zhu et al. (2004) studies), it is not known if this dependence on anatomical region is a consequence of the insertion site of the transgene or reflects profound regional differences in either promoter element activity or mRNA stability.
The 73-7 line of AxD model mice used as the genetic injury model for our study afforded another opportunity to examine the effect of a larger promoter segment while also providing a reporter gene, hGFAP, whose mRNA likely behaves similarly to the endogenous mGfap mRNA. The hGFAP transgene in this line extends from -6,156 to +11,228 (Figure 1) . As disease developed in these mice, the level of reporter hGFAP mRNA increased 49% as much as the endogenous mouse Gfap mRNA (Figure 2 ). This is a higher percentage than the response to AxD injury of any of the four WT hGFAPlacZ lines studied (14.9%, 43.2%, 10.2%, and 31.3% for WT-1 to WT-4, respectively), but is still well short of matching the endogenous mouse gene. This higher relative fold increase for the 73-7 line and the even greater increases for the mGfap-luciferase transgene just described suggest that additional injury response elements lie outside the hGFAP-lacZ transgenes used in this study. This is also suggested by the observation that the responses of the hGFAP-lacZ transgenes relative to that of the endogenous mGfap gene differed depending on the injury model. Limits for the location of such ele- One possibility is that the AP-1 binding site is indeed required for the upregulation, and the role of the JAK/STAT pathway is to activate the AP-1 transcription factors by cross-talk between the signaling pathways (reviewed in Rawlings, Rosler, & Harrison, 2004) .
In one instance, a MEK1/2 inhibitor was used to ostensibly rule out a role for AP-1 (Leung et al., 2010) , but its effect on AP-1 DNA binding was not monitored. This leaves open the possibility that AP-1 proteins were nevertheless activated.
A second explanation is that both the GFAP AP-1 and STAT binding sites are required, and act synergistically. Synergism between closely situated NF-1 and AP-1 transcription factor binding sites was noted by Gopalan et al. (2006a) for expression of the alpha1-antichymotrypsin gene in U373 glioma cells. A synergism mechanism also explains the finding that under certain circumstances JAK/ STAT signaling can be strongly stimulated without increasing GFAP transcription, indicating that activation of STAT3 alone is insufficient (Damiani & O'Callaghan, 2007; O'Callaghan, Kelly, VanGilder, Sofroniew, & Miller, 2014) . However, there are several reasons why a synergy explanation is unlikely. Using a cell culture scratch model, Gao et al. (2013) Similar to the analysis just discussed, a third possibility is that the conclusion that STAT3 is required for the Gfap injury response did not take into account that unlike AP-1, STAT3 and its GFAP promoter binding site are required for basal transcription of both the mouse and human GFAP genes (Herrmann et al., 2008; Yeo et al., 2013) .
The reduced level of promoter activity in response to injury when JAK/STAT signaling is inhibited could be due to a general effect on GFAP transcription, rather than to a reduction in the fold-increase in activity. Thus in evaluating the effect of STAT3 inhibition on the GFAP reactive response, the base line for comparison should be the uninjured state in the presence of STAT3 inhibition. This comparison is generally not made in reports addressing the role of STAT3 in the Gfap injury response, but in several instances the relevant data can be extracted from figures in the publications (Table 2 ). These data show that inhibition of JAK/STAT signaling actually had little effect on the injury-induced fold change in Gfap expression in some cases (entries 1 and 2), but in others the inhibition remained substantial, although less than that suggested in the publication.
A final possibility is that the GFAP promoter AP-1 binding site is required for the upregulation in response to some injuries, whereas STAT3 is required for others. This scenario seems unlikely because we found that the AP-1 site is critical for three very different modes of CNS injury-acute physical trauma (cryoinjury), acute chemical trauma (KA-induced excitotoxicity), and chronic degeneration (AxD). Thus, although the pathways linking each initial injury to elevated AP-1 activity are not yet delineated, our findings indicate that they converge on activation of AP-1 transcription factors as a general feature of reactive gliosis. Similarly, activation of the JAK/STAT pathway has been considered a convergent and fundamental feature for the reactive response to a variety of CNS injuries (Ceyzeriat et al., 2016) . Insults for which there is evidence that AP-1 and STAT3 activation are each essential for the reactive response include excitotoxicity (O'Callaghan et al., 2014; Pennypacker et al., 1994) and facial axotomy (Raivich et al., 2004; Tyzack et al., 2014) .
Presently, none of the above explanations is entirely satisfactory to resolve the conflicting evidence for primacy of the AP-1 or JAK/STAT signaling pathways for the GFAP response to injury.
Sorting out the distinctive contributions of each will require additional studies that include verifying the presumed effects of the pathway inhibitors used. Although the GFAP upregulation studied here is a universal feature of reactive gliosis, multiple other changes occur in reactive astrocytes, many of which are dependent on the particular conditions. Activation of STAT3 has been implicated in most of these other responses (reviewed in Ben Haim, Ceyzeriat et al., 2016) . Given our observations for GFAP upregulation, it will be of interest to explore whether AP-1 transcription factors also have a role in these additional responses. Kohro et al. (2015) , Figure 8J of Ben Haim, , and Figure 1l of Tyzack et al. (2014) for the immunofluorescence data (explicitly discussed in the text) and Figure  1m for the immunoblot data (there was no comment concerning the discrepancy between these two analyses). in Ye, Ding, Wild, Shen, & Zhou, 2014) . Our findings suggest that such drugs could also be useful for controlling the reactive response of astrocytes. In particular, they may be therapeutic for AxD, where increased production of mutant and wild-type GFAP is considered an important aspect of disease progression (Quinlan, Brenner, Goldman, & Messing, 2007) . In addition, our findings strongly suggest that an undiscovered regulatory site that contribute to the injury response of the GFAP gene resides in a region between 2.2 and 8.3 kb upstream of the hGFAP transcription start site. Lastly, we draw attention to the caveat of using FVB/N mice for neurological studies due to their propensity for spontaneous seizures.
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